Shots:

• The CodeBreaK 100 development program evaluates AMG 510 (proposed INN sotorasib- qd) in heavily pretreated patients with a range of KRAS G12C-mutant solid tumors. Eligible patients were heavily pretreated with at least 2L+ treatment and were enrolled four dose cohorts: 180 mg/360 mg/720 mg/960 mg
• This Phase 1 dose-escalation study evaluated 42 heavily pretreated patients with advanced KRAS G12C-mutant CRC. Results: 960mg cohort- ORR (12%); DCR (80%); mPFS (4.2mos.); mOS (10.1mos.); tumor shrinkage was observed in 18/39 patients with available post-baseline tumor data across all doses
• Data were evaluated for 25 heavily pretreated patients with advanced KRAS G12C-mutant solid tumors other than CRC or NSCLC. These patients had received a median 3L+ with a median follow-up of 4.3mos. The P-II study in NSCLC is on track for data readout in 2020 while the P-II CRC trial is expected to have a data readout in early 2021

Click here to­ read full press release/ article | Ref: Amgen | Image: Livemint